Literature DB >> 31128026

L-Tetrahydropalmatine enhances the sensitivity of human ovarian cancer cells to cisplatin via microRNA-93/PTEN/Akt cascade.

Jian Gong1, Chao Xing, Lian Yun Wang, Shuang Shuang Xie, Wen Dong Xiong.   

Abstract

PURPOSE: Το evaluate the effect of L-Tetrahydropalmatine (L-THP) on the sensitivity of a cisplatin resistant ovarian cancer (OC) cell line. As miR-93 is reported to be overexpressed in OC and cisplatin resistance, we also evaluated its pathway in OC.
METHODS: The levels of miR-93 were evaluated using RT-PCR and Luciferase assay was performed to confirm the target of miR-93. The extent of apoptosis was evaluated by Annexin V and propidium iodide (PI) staining, whereas Hoechst 33258 staining was done for identifying the number of apoptotic cells.
RESULTS: The cisplatin-resistant A2780/DDP cell line showed lower survival rate compared to control when incubated with L-THP along with cisplatin. L-THP caused G0/G1 cell cycle arrest and increased the sensitivity to cisplatin. Furthermore, we found that the levels of miR-93 in cisplatin-resistant cells were highly expressed compared to parental cells. L-THP suppressed the expression of miR-93 and increased the levels of PTEN, a crucial tumor suppressor in OC. It was further observed that the cells transfected with PTEN siRNA showed increased survival compared with the control group and this phenomenon could be reversed by the AKT inhibitor Triciribine. The A2780 cells treated with PTEN siRNA showed similar survival rate to the cells with miR-93 overexpression.
CONCLUSION: The findings of this study suggested L-THP increased the sensitivity of ovarian cancer cells to cisplatin via modulating miR-93/PTEN/AKT pathway in A2780/DDP ovarian cancer cell line.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31128026

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  6 in total

Review 1.  A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview.

Authors:  Ahmad Saburi; Mohammad Saeed Kahrizi; Navid Naghsh; Hasti Etemadi; Ahmet İlhan; Ali Adili; Shadi Ghoreishizadeh; Rozita Tamjidifar; Morteza Akbari; Gülinnaz Ercan
Journal:  J Ovarian Res       Date:  2022-07-07       Impact factor: 5.506

2.  Exosomal MicroRNA as Biomarkers for Diagnosing or Monitoring the Progression of Ovarian Clear Cell Carcinoma: A Pilot Study.

Authors:  Kayo Horie; Naoki Nanashima; Yoshihito Yokoyama; Haruhiko Yoshioka; Jun Watanabe
Journal:  Molecules       Date:  2022-06-20       Impact factor: 4.927

Review 3.  Flaming the fight against cancer cells: the role of microRNA-93.

Authors:  Milad Ashrafizadeh; Masoud Najafi; Reza Mohammadinejad; Tahereh Farkhondeh; Saeed Samarghandian
Journal:  Cancer Cell Int       Date:  2020-06-29       Impact factor: 5.722

Review 4.  A Comprehensive Review on the Chemical Properties, Plant Sources, Pharmacological Activities, Pharmacokinetic and Toxicological Characteristics of Tetrahydropalmatine.

Authors:  Qinyun Du; Xianli Meng; Shaohui Wang
Journal:  Front Pharmacol       Date:  2022-04-26       Impact factor: 5.988

5.  lncRNA PVT1/MicroRNA-17-5p/PTEN Axis Regulates Secretion of E2 and P4, Proliferation, and Apoptosis of Ovarian Granulosa Cells in PCOS.

Authors:  Gelin Liu; Shengxian Liu; Guanlin Xing; Fang Wang
Journal:  Mol Ther Nucleic Acids       Date:  2020-02-13       Impact factor: 8.886

6.  Long non‑coding RNA HAND2‑AS1/miR‑106a/PTEN axis re‑sensitizes cisplatin‑resistant ovarian cells to cisplatin treatment.

Authors:  Lijun Li; Li Li; Lian Hu; Ting Li; Dan Xie; Xiaoliu Liu
Journal:  Mol Med Rep       Date:  2021-09-03       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.